Results of a tailored multimodal lifestyle follow-up care program focusing on physical activity, nutritional behavior and psychological processes in adolescent and young adult cancer survivors: The CARE for CAYA multicenter, randomized clinical trial.

Authors

null

Simon Elmers

Hubertus Wald Tumor Center - University Cancer Center Hamburg, University Medical Center Hamburg-Eppendorf, Hamburg, Germany

Simon Elmers , Julia von Grundherr , Gabriele Calaminus , Jorg Faber , Judith Gebauer , Miriam Götte , Inken Hilgendorf , Michael Koehler , Alexander Puzik , Anette Sander , Nicole Salzmann , Lisa Schiffmann , Sonja Schuster , Magdalena Sokalska-Duhme , Alexander Stein , Sarah Dwinger , Eik Vettorazzi , Jannike Lisa Salchow , Carsten Bokemeyer , Marianne Sinn

Organizations

Hubertus Wald Tumor Center - University Cancer Center Hamburg, University Medical Center Hamburg-Eppendorf, Hamburg, Germany, Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany, Department of Pediatric Hematology and Oncology, University Hospital Bonn, Bonn, Germany, Children's University Hospital, Mainz, Germany, Department of Internal Medicine I, University Hospital of Schleswig-Holstein, Campus Luebeck, Lübeck, Germany, Clinic for Pediatrics III, Department of Pediatric Hematology/Oncology, West German Cancer Centre, University Hospital Essen, Essen, Germany, Klinik für Innere Medizin II, Abteilung für Hämatologie und Internistische Onkologie, Universitätsklinikum Jena, Jena, Germany, Specialty Practice for Psycho-Oncology, Magdeburg, Magdeburg, Germany, Department of Pediatric Hematology and Oncology, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany, Medizinische Hochschule Hannover, Klinik für Pädiatrische Hämatologie -Onkologie, Hannover, Germany, University Children's Hospital Muenster, Pediatric Hematology and Oncology, Münster, Germany, Institut für Klinische Epidemiologie und Biometrie, Julius-Maximilians-Universität Würzburg, Würzburg, Germany CCC WERA, Komplementäre Onkologie Integrativ, Universitätsklinikum Würzburg, Würzburg, Germany, Abteilung Für Pädiatrische Hämatologie Und Onkologie, Kinder- Und Jugendklinik, Universitätsklinikum Erlangen, Erlangen, Germany, Department of Pediatric Hematology, Onkology & Immunology, Olgahospital, Klinikum Stuttgart, Stuttgart, Germany, Hämatologisch-Onkologische Praxis Eppendorf (HOPE) and University Cancer Center Hamburg (UCCH), Hamburg, Germany, Department for Medical Psychology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany, University Medical Center Hamburg-Eppendorf, Hamburg, Germany, University Medical Center HH-Eppendorf, Hamburg, Germany, Department of Oncology, Hematology and Bone Marrow Transplantation with Section of Pneumology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany, Universitätsklinikum Hamburg-Eppendorf II. Medizinische Klinik, Hamburg, Germany

Research Funding

Other Foundation
Federal Joint Committee

Background: The aim of the CARE for CAYA-program (CFC-P) was to implement a multimodal lifestyle program in addition to medical follow-up care for child, adolescents and young adult cancer survivors (CAYAs). Methods: The CFC-P was a multicenter program with an initial randomized clinical trial (RCT) comparing need-based modular interventions to usual care for CAYAs aged between 15 and 39. A comprehensive assessment (questionnaires and medical examination) was conducted to determine individual needs regarding nutrition, physical activity and psycho-oncology. If “high need” was identified, CAYAs could take part in up to three modules over 12 months. In the intervention group (IG), each module included five consultations plus newsletters. The control group (CG) included one baseline counseling in each module. The primary outcome was defined as the rate of CAYAs with “high need(s)” after 12 months of intervention. Secondary outcomes included feasibility, cost-effectiveness, modular-specific endpoints, quality of life (QoL) and fatigue. Results: 791 CAYAs were included at 14 German CAYA survivorship clinics from December 2017 to March 2021. Most common tumor types were lymphoma 26.8% (n = 211), sarcoma 13.2% (n = 104) and leukemia 10.0% (n = 79). 58.0% (n = 457) were female, median age was 23.9 years, time since end of tumor specific therapy was < 5 years in 54.4%, > 5 years in 21.2%, > 10 years in 11.5% and > 15 years in 12.9% of patients (median: 57.0 months). 86.2% (n = 679) reported an initial “high need” in at least one module. After 52 weeks, 83.9% (n = 396 of 472 evaluable participants) continued to report or developed a “high need”: 59.3% (n = 235) in IG and non-randomized cohort, 28.8% (n = 114) in CG and 12.7% (n = 47) with no initial “high need”. 357 participants were evaluable in the RCT (63% (n = 226) female, median age 25.0 years). 26.2% (n = 94) reported a “high need” in one, 35.7% (n = 128) in two and 37.6% (n = 135) in three modules. 271 patients could be analyzed at 52 weeks, 87.0% of IG (n = 120 of 138) and 86.5% of CG (n = 115 of 133) continued to have at least one “high need”. The primary outcome did not differ significantly between groups (p = .905). However, both showed an increase of QoL and a reduction of fatigue. Conclusions: In the CFC-P, the feasibility of a large trial to regularly assess lifestyle habits and the psychosocial situation and determine the efficacy of a need based multimodal interventions in CAYAs was demonstrated. Although a high need for support was revealed in this population, no significant changes with the applied interventions were noted after 12 months. The obtained data will guide the development and implementation of multimodal interventions in long term follow up of CAYAs. Clinical trial information: DRKS00012504.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Abstract Details

Meeting

2023 ASCO Annual Meeting

Session Type

Oral Abstract Session

Session Title

Symptoms and Survivorship

Track

Symptom Science and Palliative Care

Sub Track

Late and Long-Term Adverse Effects

Clinical Trial Registration Number

DRKS00012504

Citation

J Clin Oncol 41, 2023 (suppl 16; abstr 12002)

DOI

10.1200/JCO.2023.41.16_suppl.12002

Abstract #

12002

Abstract Disclosures

Similar Abstracts

Abstract

2023 ASCO Annual Meeting

National Coalition for Cancer Survivorship State of Survivorship Survey.

First Author: Shelley Fuld Nasso

First Author: Spencer Soberano

First Author: Lauren Victoria Ghazal